GILEAD SCIENCES revenue breakdown overview

GILEAD SCIENCES revenue for the last year amounted to 27.78 B EUR, the most of which — 18.94 B EUR — came from its highest performing source at the moment, Human Immunodeficiency Virus, the year earlier bringing 16.47 B EUR. The greatest contribution to the revenue figure was made by United States — last year it brought GILEAD SCIENCES 19.89 B EUR, and the year before that — 17.61 B EUR.